On 01 February 2023, 7:30 CET our full-year 2022 financial results will be released. The company announcement will be available here
On the same day, please join the earnings conference call,
to learn more about our full-year results:
13.00-14.00 (CET)
12.00-13.00 (GMT)
07.00-08.00 (EST)
Conference call webcast, click here
To access the earnings call and to ask questions, please register here
Conference call webcast (3 August at 19:30 CEST)
London conference call webcast (5 August at 14:15 CEST)
London earnings presentation conference call (5 May 2022, 14.15 CEST)
Conference call webcast (29 April 2022, 13:00 CEST)
5 June: Investor event (ADA 82nd Scientific Sessions)
Presentation (Webcast)
Presentation (pdf)
20 December: Conference call on supply situation for Wegovy®
28 June: R&D investor call
07 June: Approval of Wegovy™ in the US
21 May: International Operations call
25 March: Annual General Meeting
16 December: Decision to enter phase 3 development in Alzheimer’s disease and GLP-1 R&D strategy update
30 November: ESG conference call
9 October: Novo Nordisk raises sales and operating profit
outlook for 2020
19 June: R&D investor presentation
26 March: Annual General Meeting
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Investors
Share price
{{priceData.date}} {{priceData.time}}